SOURCE: Corporate Profile LLC

Corporate Profile LLC

August 16, 2011 07:00 ET

Oramed Pharmaceuticals CEO Nadav Kidron Interviewed on

NEW YORK, NY--(Marketwire - Aug 16, 2011) - Corporate Profile, LLC announced today that Oramed Pharmaceuticals, Inc. (OTCBB: ORMP) (OTCQB: ORMP) CEO, Nadav Kidron, was interviewed on

The video can be viewed at:

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in Phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research performed by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit

Corporate Profile LLC
Corporate Profile® is an online informational network of financial websites including: which is a broadcasting website where fashion meets finance providing updates from up and coming small and microcap companies as well as interesting interviews and financial news. provides access to cutting edge investment newsletters and small cap reports.
For more info please visit: and

Safe Harbor Disclaimer
Under The Private Securities Litigation Reform Act of 1995: Except for historical information contained herein, the statements in this news release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause a company's actual results, performance and achievement in the future to differ materially from forecasted results, performance, and achievement. These risks and uncertainties are described in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectation.